Compare Lionsgate Studios Corp Common Shares (LION) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lionsgate Studios Corp Common Shares vs Tilray Brands Inc — how do they compare? Lionsgate Studios Corp Common Shares trades at $10.89 (market cap $3.24B), while Tilray Brands Inc trades at $3.07 (market cap $463.31M). The key difference: Lionsgate Studios Corp Common Shares is far larger — about 7× Tilray Brands Inc's market cap, and Lionsgate Studios Corp Common Shares is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Lionsgate Studios Corp Common Shares for 0 Days and Tilray Brands Inc for 31 Days on average.
| LION | TLRY | |
|---|---|---|
Market Cap | $3.24B | $463.31M |
Volume | 3,214,595 | 4,627,093 |
Sector | Technology | Health |
52-Week High | $16.40 | $16.80 |
52-Week Low | $5.91 | $3.14 |
Typical Hold Time | 0 Days | 31 Days |
Enterprise Value | $6.75B | $617.23M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LION trades at $11.12, up 0.36% on the day, with a market cap of approximately $1.3 billion. The stock shows mixed signals: strong analyst support (87.5% buy rating) and a consensus price target of $16.80 suggest upside, but negative net income and shareholder equity highlight financial strain. Recent Q1 2027 earnings beat estimates with EPS of $0.37, yet the company remains unprofitable with a net loss of $128.5 million in 2025. Takeover interest from firms like Bolloré adds speculative appeal.
The outlook hinges on operational turnaround and potential M&A. Revenue growth from hit films like 'Michael' and a valuable content library offer catalysts, but high debt ($3.65B total) and consistent losses pose significant risks. Investors should weigh the 51% upside to price targets against fundamental weaknesses and industry volatility.
TLRY trades at $3.27, down 2.68% on the day and near 52-week lows, reflecting persistent bearish pressure. The stock's technical indicators are mixed but overall signal remains negative. Fundamentally, the company reported a net loss of $2.19 billion in 2025 despite $821 million in revenue, with profitability metrics deeply negative. Recent news highlights continued stock weakness and strategic brand expansions under Tilray ownership.
The outlook is highly speculative; TLRY faces significant execution and profitability challenges, though analyst consensus suggests substantial upside potential from current levels. Key risks include ongoing losses, high debt levels, and regulatory uncertainty in the cannabis sector. Investment suitability is limited to high-risk tolerance investors betting on a operational turnaround or favorable regulatory shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lionsgate Studios Corp Common Shares
Lionsgate Studios Corp. is a standalone content company that develops, finances, produces, and distributes motion pictures and television series, licensing its content to theaters, streaming platforms, television networks, and home entertainment channels.
Read more on LION →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
